Refractory Cancer Clinical Trials

55 clinical trials for Refractory Cancer across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer — RECRUITING · PHASE1
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma — RECRUITING · PHASE2
• Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC — RECRUITING · PHASE1
• IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors — RECRUITING · PHASE1
• Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma — RECRUITING · PHASE2
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors — RECRUITING · PHASE1
• Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer — RECRUITING · PHASE2
• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas — RECRUITING · PHASE2
• Pembrolizumab, Ibrutinib and Rituximab in PCNSL — RECRUITING · PHASE1
• Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer — RECRUITING · PHASE1
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors — RECRUITING · PHASE1
• Plan Development for Giving Teclistamab in the Outpatient Setting — RECRUITING · PHASE4
• A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. — RECRUITING · PHASE1
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies — RECRUITING · PHASE1
• Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) — RECRUITING · PHASE1
• Precision Medicine for Every Child With Cancer — RECRUITING
• Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations — RECRUITING · PHASE2
• Individualized Treatments in Adults With Relapsed/Refractory Cancers — COMPLETED · NA
• A Study of Avutometinib for People With Solid Tumor Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor — ACTIVE_NOT_RECRUITING · PHASE1
• 9-ING-41 in Patients With Advanced Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults — COMPLETED · PHASE1
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• 9-ING-41 in Pediatric Patients With Refractory Malignancies. — TERMINATED · PHASE1
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer — TERMINATED · PHASE1
• Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling — COMPLETED
• TCR-engineered T Cells in Solid Tumors: IMA202-101 — COMPLETED · PHASE1
• A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy — COMPLETED · PHASE1
• A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors — COMPLETED · PHASE1
• A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors — WITHDRAWN · PHASE1
• Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS — COMPLETED · PHASE1
• Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents — COMPLETED · NA
• PRecISion Medicine for Children With Cancer — ACTIVE_NOT_RECRUITING
• Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers — TERMINATED · PHASE1
• Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy — COMPLETED · PHASE1
• A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer — COMPLETED · PHASE1
• Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer — OTHER · PHASE2
• Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors — WITHDRAWN · PHASE1
• myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports — OTHER
• Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents — COMPLETED · NA
• BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer — TERMINATED · PHASE2
• Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer — COMPLETED · PHASE1
• Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies — OTHER · PHASE1
• A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors — OTHER · PHASE1
• Arsenic Trioxide for Structural p53 Mutations — OTHER · PHASE2
• Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors — COMPLETED · PHASE1
• Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL — OTHER · PHASE2

Refine this search